Clinical trial · Observational
Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board
Feasibility of Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board in Cancer Patients
NCT04343365CI-TRIAL-00107057recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Incurable Disease | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Evolutionary Tumor Board (ETB) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Participants Reviewed by ETB
- description
- Participants clinical history, available therapeutic options, and outcome expectations will be presented to the Evolutionary Tumor Board (ETB) along with images and pathology. Strategies and models will be presented regarding additional evolutionary ideas that can be applied.
- interventionNames
- Other: Evolutionary Tumor Board (ETB)
Primary outcomes (1)
- measure
- ETB developing therapeutic strategies
- timeFrame
- Baseline to up to 60 months from end of therapy
- description
- The investigators want to demonstrate the ability of a multidisciplinary group, the ETB, to develop therapeutic strategies in participants without curative options. They plan to enroll 35 patients to this study over 3 years. The primary objective will be successfully met if they can develop an evolutionary based plan that differs from the participants options prior to presentation for at least 80%, or 28 of these participants.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Participant must be considered likely incurable given a standard of care. This is inclusive of participants in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but not curative options for care. * Participant must have a life expectancy greater than 3 months * Participant must have an ECOG performance status 0-2 * Participant and primary Oncologist are willing to consider the therapeutic strategies recommended by the ETB * Willingness to be followed over time and allowing collection of clinical data including scans and serial blood sampling. Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.